Literature DB >> 29983395

CD24 and Fc fusion protein protects SIVmac239-infected Chinese rhesus macaque against progression to AIDS.

Ren-Rong Tian1, Ming-Xu Zhang2, Lin-Tao Zhang1, Peng Zhang3, Jian-Ping Ma4, Mingyue Liu3, Martin Devenport5, Pan Zheng6, Xiao-Liang Zhang1, Xiao-Dong Lian2, Mei Ye2, Hong-Yi Zheng1, Wei Pang1, Gao-Hong Zhang1, Li-Guo Zhang7, Yang Liu8, Yong-Tang Zheng9.   

Abstract

Chronic immune activation and systemic inflammation are underlying causes of acquired immunodeficiency syndrome (AIDS). Products of virus replication and microbial translocation, co-infection or opportunistic pathogens, and danger-associated molecular patterns have been reported to contribute to chronic immune activation and inflammation in human immunodeficiency virus type-1/simian immunodeficiency virus (HIV-1/SIV) infection or other disease. To develop new strategies and therapies for HIV-1/AIDS, we tested if the CD24 and Fc fusion protein (CD24Fc), which interacts with danger-associated molecular patterns and sialic acid binding Ig-like lectin to attenuate inflammation, can protect Chinese rhesus macaques (ChRMs) with SIV infection. We found that CD24Fc treatment decreased weight loss, wasting syndrome, intractable diarrhea, and AIDS morbidity and mortality, while it was well tolerated by SIV-infected animals. Corresponding to the elimination of intractable diarrhea, CD24Fc significantly reduced the expression of IL-6 and indoleamine 2, 3-dioxygenase-1 in peripheral blood mononuclear cell and inflammation in the ileum, colon and rectum based on the reduction of inflammatory cells, pathological scores and expression of inflammatory cytokines. Furthermore, although CD24Fc did not restore CD4+ T cell number or significantly change T cell subsets or CD4+ T cell activation, it maintained low levels of plasma soluble CD14, CD8+ T cell activation, viral load and proviral load in the peripheral blood mononuclear cells and marrow. These results suggested that CD24Fc confers protection to SIV-infected ChRMs against progression to AIDS. It was also implied that CD24Fc may be a potential therapeutic approach for the control of HIV-1/AIDS.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AIDS; CD24Fc fusion protein; Chinese rhesus macaques; Inflammation; Simian immunodeficiency virus

Mesh:

Substances:

Year:  2018        PMID: 29983395     DOI: 10.1016/j.antiviral.2018.07.004

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  16 in total

1.  CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder.

Authors:  Xu Wang; Mingyue Liu; Jifeng Zhang; Nicholas K Brown; Peng Zhang; Yan Zhang; Heng Liu; Xuexiang Du; Wei Wu; Martin Devenport; Weng Tao; Yang Mao-Draayer; Guo-Yun Chen; Y Eugene Chen; Pan Zheng; Yang Liu
Journal:  Cell Metab       Date:  2022-08-02       Impact factor: 31.373

Review 2.  COVID-19 and Cancer: a Comprehensive Review.

Authors:  Rohit Gosain; Yara Abdou; Abhay Singh; Navpreet Rana; Igor Puzanov; Marc S Ernstoff
Journal:  Curr Oncol Rep       Date:  2020-05-08       Impact factor: 5.075

3.  Synthetic Siglec-9 Agonists Inhibit Neutrophil Activation Associated with COVID-19.

Authors:  Corleone S Delaveris; Aaron J Wilk; Nicholas M Riley; Jessica C Stark; Samuel S Yang; Angela J Rogers; Thanmayi Ranganath; Kari C Nadeau; Catherine A Blish; Carolyn R Bertozzi
Journal:  ChemRxiv       Date:  2020-12-17

4.  Synthetic Siglec-9 Agonists Inhibit Neutrophil Activation Associated with COVID-19.

Authors:  Corleone S Delaveris; Aaron J Wilk; Nicholas M Riley; Jessica C Stark; Samuel S Yang; Angela J Rogers; Thanmayi Ranganath; Kari C Nadeau; Catherine A Blish; Carolyn R Bertozzi
Journal:  ACS Cent Sci       Date:  2021-03-24       Impact factor: 14.553

Review 5.  An overview of some potential immunotherapeutic options against COVID-19.

Authors:  Maryam Bayat; Yahya Asemani; Mohammad Reza Mohammadi; Mahsa Sanaei; Mozhdeh Namvarpour; Reyhaneh Eftekhari
Journal:  Int Immunopharmacol       Date:  2021-02-26       Impact factor: 5.714

6.  Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology.

Authors:  No-Joon Song; Carter Allen; Anna E Vilgelm; Brian P Riesenberg; Carlos D Malvestutto; Dongjun Chung; Zihai Li; Kevin P Weller; Kelsi Reynolds; Karthik B Chakravarthy; Amrendra Kumar; Aastha Khatiwada; Zequn Sun; Anjun Ma; Yuzhou Chang; Mohamed Yusuf; Anqi Li; Cong Zeng; John P Evans; Donna Bucci; Manuja Gunasena; Menglin Xu; Namal P M Liyanage; Chelsea Bolyard; Maria Velegraki; Shan-Lu Liu; Qin Ma; Martin Devenport; Yang Liu; Pan Zheng
Journal:  J Hematol Oncol       Date:  2022-01-10       Impact factor: 23.168

7.  Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19.

Authors:  Aaron J Wilk; Madeline J Lee; Bei Wei; Benjamin Parks; Ruoxi Pi; Giovanny J Martínez-Colón; Thanmayi Ranganath; Nancy Q Zhao; Shalina Taylor; Winston Becker; David Jimenez-Morales; Andra L Blomkalns; Ruth O'Hara; Euan A Ashley; Kari C Nadeau; Samuel Yang; Susan Holmes; Marlene Rabinovitch; Angela J Rogers; William J Greenleaf; Catherine A Blish
Journal:  J Exp Med       Date:  2021-06-15       Impact factor: 17.579

Review 8.  Countermeasures to Coronavirus Disease 2019: Are Immunomodulators Rational Treatment Options-A Critical Review of the Evidence.

Authors:  Daniel B Chastain; Tia M Stitt; Phong T Ly; Andrés F Henao-Martínez; Carlos Franco-Paredes; Sharmon P Osae
Journal:  Open Forum Infect Dis       Date:  2020-06-05       Impact factor: 3.835

Review 9.  Immunotherapeutic approaches to curtail COVID-19.

Authors:  Hajar Owji; Manica Negahdaripour; Nasim Hajighahramani
Journal:  Int Immunopharmacol       Date:  2020-08-21       Impact factor: 4.932

Review 10.  Post-Translational Modification of HMGB1 Disulfide Bonds in Stimulating and Inhibiting Inflammation.

Authors:  Ulf Andersson; Kevin J Tracey; Huan Yang
Journal:  Cells       Date:  2021-11-26       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.